View of Stockholm through window

Sobi’s shareholders receive recommended public cash offer from Advent and GIC

Sobi is advised by Mannheimer Swartling in relation to the recommended public cash offer to the shareholders in Sobi by Advent and GIC, through Agnafit Bidco.

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications.

The offer values Sobi at approximately SEK 69.4 billion.


This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.